Retour
Prix Prokidney Corp (PROK)
Graphique du cours de l'action PROK
PROK Gagner
Prokidney Corp
$2.14
-6.55%
$-0.14
À la fermeture : Jan 20, 16:00:00 GMT-5
$2.17
1.4%
$0.02
Post-Marché: Jan 20, 17:37:01 GMT-5
Statistiques clés
Clôture préc.
$2.29
Prix d'ouverture
$2.19
Plage de la journée
$2.12 - $2.24
Plage de 52 semaines
$0.46 - $7.13
Volume
1.3M
Volume moyen
1.3M
BPA (TTM)
-0.54
Rendement en dividend
--
Capitalisation boursière
$652.8M
Qu’est-ce que PROK ?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved